Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CureVac NV CVAC

Healthcare Biotechnology
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people’s lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.

Recent & Breaking News (NDAQ:CVAC)

CureVac Announces Pricing of $450 million Follow-on Public Offering of Common Shares

Accesswire January 28, 2021

CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection

Accesswire January 11, 2021

CureVac : CureVac and Bayer Join Forces on COVID-19 Vaccine Candidate CVnCoV

Accesswire January 7, 2021

CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare Workers

Accesswire December 21, 2020

CureVac : CureVac Commences Global Pivotal Phase 2b/3 Trial for COVID-19 Vaccine Candidate, CVnCoV

Accesswire December 14, 2020

CureVac Appoints Antony Blanc as Chief Business Officer and Chief Commercial Officer

Accesswire December 4, 2020

CureVac Announces Financial Results and Business Updates for the Third Quarter and First Nine Months of 2020

Accesswire November 30, 2020

CureVac to Report Third Quarter and First Nine Months 2020 Financial Results and Business Updates on November 30, 2020

Accesswire November 26, 2020

CureVac Establishes European-Based Network to Ramp Up Manufacturing of its COVID-19 Vaccine Candidate, CVnCoV

Accesswire November 17, 2020

European Commission Announces That Tomorrow It Will Authorize the Agreement with CureVac for the Supply of up to 405 Million Doses of mRNA-Based COVID-19 Vaccine Candidate, CVnCoV

Accesswire November 16, 2020

CureVac Publishes Detailed Interim Phase 1 Data of its COVID-19 Vaccine Candidate, CVnCoV

Accesswire November 10, 2020

CureVac Reports Positive Interim Phase 1 Data for its COVID-19 Vaccine Candidate, CVnCoV

Accesswire November 2, 2020

CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV

Accesswire October 23, 2020

CureVac: CureVac Initiates Phase 2a Clinical Trial of COVID-19 Vaccine Candidate

Accesswire September 29, 2020

CureVac Expected to Receive up to 252 million Euros from the German Federal Ministry of Research for Further COVID-19 Vaccine Development and Production Capacity Expansion

Accesswire September 4, 2020